default-logo

May: AcuImmune is one of 25 organizations globally taking part in External Quality Assurance Program Oversight Laboratory (EQAPOL) Luminex proficiency testing. In May 2015, AcuImmune completed its 9th round of EQAPOL Luminex quality assurance analysis. EQAPOL is a joint initiative of the National Institute of Allergy and Infectious Diseases and Cancer Immunotherapy Consortium (CIC) at Duke University’s Human Vaccine Institute.

April: Scientists from AcuImmune present poster titled, “Multiplexed Analysis of Inflammatory Cytokines as Biomarkers in Moderate-Advanced Periodontal Disease and Systemic Conditions” at SoCal Flow Summit 2015 in Irvine, CA.  To view, click here.

March: AcuImmune submits Small Business Innovation Research (SBIR) grant to NIH for novel allergy diagnostic. Components of the assay are designed through collaboration with EpiVax. Details to follow, pending review.